Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37082840 | 1.00 | GSK3B (0.48) | GSK3BDGAT1CES2PTPN1HPGD | |
| SCHEMBL15900302 | 0.85 | DGAT1 (0.47) | DGAT1CES2HPGDGALR3CYP1A2 | |
| SCHEMBL29993519 | 0.85 | DGAT1 (0.61) | GSK3BDGAT1CES2PTPN1HPGD | |
| SCHEMBL691531 | 0.85 | DGAT1 (0.61) | GSK3BDGAT1CES2PTPN1HPGD | |
| SCHEMBL182358 | 0.83 | DGAT1 (0.46) | DGAT1CES2HPGDGALR3CYP1A2 | |
| SCHEMBL2099037 | 0.82 | CES2 (0.61) | GSK3BCES2PTPN1HPGDALDH1A1 | |
| SCHEMBL31678827 | 0.81 | GSK3B (0.52) | GSK3BCES2PTPN1HPGDALOX15 | |
| SCHEMBL3930687 | 0.81 | GSK3B (0.52) | GSK3BCES2PTPN1HPGDALOX15 | |
| SCHEMBL1145090 | 0.80 | ALDH1A1 (0.44) | DGAT1CES2HPGDGALR3CYP1A2 | |
| SCHEMBL30040752 | 0.80 | GSK3B (0.52) | GSK3BCES2PTPN1HPGDGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353163-B1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-05 | — | — | EP | disclosed |
| EP-3250575-B1 | TOSYLATE SALT OF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHENYL]-5-METHOXY-PYRAZINE-2-CARBOXAMIDE. | LILLY CO ELI (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3250575-B1 | TOSYLATE SALT OF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHENYL]-5-METHOXY-PYRAZINE-2-CARBOXAMIDE. | LILLY CO ELI (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3194408-B1 | A TETRAHYDROPYRROLO[3,4-D][1,3]THIAZINE-DERIVATIVE AS BACE INHIBITOR | LILLY CO ELI (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3194408-B1 | A TETRAHYDROPYRROLO[3,4-D][1,3]THIAZINE-DERIVATIVE AS BACE INHIBITOR | LILLY CO ELI (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20180334447-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-22 | — | — | US | disclosed |
| US-10080758-B2 | Tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide | ELI LILLY AND COMPANY (US) | 2018-09-25 | — | — | US | disclosed |
| EP-3353163-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2018-08-01 | — | — | EP | disclosed |
| US-9999624-B2 | Combination Alzheimer therapy using anti-N3pGlu Abeta antibodies + a BACE inhibitor | ELI LILLY AND COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| US-9999624-B2 | Combination Alzheimer therapy using anti-N3pGlu Abeta antibodies + a BACE inhibitor | ELI LILLY AND COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170224702-A1 | COMBINATION ALZHEIMER THERAPY USING ANTI-N3PGLU ABETA ANTIBODIES + A BACE INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224702-A1 | COMBINATION ALZHEIMER THERAPY USING ANTI-N3PGLU ABETA ANTIBODIES + A BACE INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224702-A1 | COMBINATION ALZHEIMER THERAPY USING ANTI-N3PGLU ABETA ANTIBODIES + A BACE INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3193882-A1 | COMBINATION ALZHEIMER THERAPY USING ANTI-N3PGLU ABETA ANTIBODIES + A BACE INHIBITOR | Eli Lilly and Company (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017050978-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | WO | disclosed |
| WO-2016122968-A1 | TOSYLATE SALT OF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHENYL]-5-METHOXY-PYRAZINE-2-CARBOXAMIDE | ELI LILLY AND COMPANY (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016122968-A1 | TOSYLATE SALT OF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHENYL]-5-METHOXY-PYRAZINE-2-CARBOXAMIDE | ELI LILLY AND COMPANY (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016043997-A1 | COMBINATION ALZHEIMER THERAPY USING ANTI-N3PGLU ABETA ANTIBODIES + A BACE INHIBITOR | ELI LILLY AND COMPANY (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016043997-A1 | COMBINATION ALZHEIMER THERAPY USING ANTI-N3PGLU ABETA ANTIBODIES + A BACE INHIBITOR | ELI LILLY AND COMPANY (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016043996-A1 | A TETRAHYDROPYRROLO[3,4-D][1,3]THIAZINE-DERIVATIVE AS BACE INHIBITOR | ELI LILLY AND COMPANY (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224702-A1 | COMBINATION ALZHEIMER THERAPY USING ANTI-N3PGLU ABETA ANTIBODIES + A BACE INHIBITOR | BACE1, BACE2, PSEN1 | GSK3B 456/4885DGAT1 2344/4885CES2 3134/4885 |
| US-20180334447-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | BACE1, BACE2, APP | GSK3B 90/4885DGAT1 2040/4885CES2 1559/4885 |
| US-10080758-B2 | Tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide | NT5C, ABL1, NT5M | GSK3B 4254/4885DGAT1 4272/4885CES2 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.